MADRID, November 14, 2017 /PRNewswire/ --
PharmaMar (MCE: PHM) will present and meet institutional investors in onone meetings at the Stifel Nicolaus Weisel Healthcare Conference on November 15th in New York City. The presentation will take place on Wednesday November 15th
(Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )
To access a live audio webcast of the presentation, please visit http://wsw.com/webcast/stifel10/Pharma Mar/
A webcast replay will be available on the PharmaMar website for 90 days following the call by visiting the same link http://wsw.com/webcast/stifel10/Pharma Mar/
Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has other clinical-stage programs under development for several types of solid and hematological cancers, Zepsyre® (PM1183), plitidepsin, PM184 and PM14. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium, Austria and the United States. PharmaMar fully owns other companies: GENOMICA, leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at http://www.pharmamar.com.
Contact: Media Relations (+34-638-79-62-15) and Investor Relations (+34-914444500)
Subscribe to our Free Newsletters!
Abruptio placenta is a serious but rare complication of pregnancy where a separation of placenta ...
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...View All